JP2025073123A5 - - Google Patents
Info
- Publication number
- JP2025073123A5 JP2025073123A5 JP2025016352A JP2025016352A JP2025073123A5 JP 2025073123 A5 JP2025073123 A5 JP 2025073123A5 JP 2025016352 A JP2025016352 A JP 2025016352A JP 2025016352 A JP2025016352 A JP 2025016352A JP 2025073123 A5 JP2025073123 A5 JP 2025073123A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nucleotide
- pharmaceutical composition
- sequence
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817904P | 2019-03-13 | 2019-03-13 | |
| US62/817,904 | 2019-03-13 | ||
| US201962856432P | 2019-06-03 | 2019-06-03 | |
| US62/856,432 | 2019-06-03 | ||
| JP2021554696A JP2022524434A (ja) | 2019-03-13 | 2020-03-13 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| PCT/US2020/022738 WO2020186207A2 (en) | 2019-03-13 | 2020-03-13 | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554696A Division JP2022524434A (ja) | 2019-03-13 | 2020-03-13 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025073123A JP2025073123A (ja) | 2025-05-12 |
| JP2025073123A5 true JP2025073123A5 (enExample) | 2025-08-06 |
Family
ID=72426821
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554696A Pending JP2022524434A (ja) | 2019-03-13 | 2020-03-13 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025016352A Pending JP2025073123A (ja) | 2019-03-13 | 2025-02-03 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554696A Pending JP2022524434A (ja) | 2019-03-13 | 2020-03-13 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12338275B2 (enExample) |
| EP (1) | EP3938523A4 (enExample) |
| JP (2) | JP2022524434A (enExample) |
| KR (1) | KR20210151785A (enExample) |
| CN (1) | CN113874513A (enExample) |
| AU (1) | AU2020234713A1 (enExample) |
| BR (1) | BR112021017853A2 (enExample) |
| CA (1) | CA3133255A1 (enExample) |
| IL (1) | IL286284A (enExample) |
| MA (1) | MA55313A (enExample) |
| MX (1) | MX2021011039A (enExample) |
| SG (1) | SG11202109850SA (enExample) |
| WO (1) | WO2020186207A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019032898A1 (en) | 2017-08-09 | 2019-02-14 | Bioverativ Therapeutics Inc. | NUCLEIC ACID MOLECULES AND USES THEREOF |
| SG11202101157VA (en) | 2018-08-09 | 2021-03-30 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| WO2022023284A1 (en) | 2020-07-27 | 2022-02-03 | Anjarium Biosciences Ag | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| US20220356490A1 (en) * | 2020-08-23 | 2022-11-10 | Bioverativ Therapeutics Inc. | Baculovirus expression system |
| JP2024538168A (ja) * | 2021-10-18 | 2024-10-18 | フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー | Ｄｎａ組成物及び関連方法 |
| WO2023078220A1 (zh) * | 2021-11-02 | 2023-05-11 | 苏州华毅乐健生物科技有限公司 | 分离的核酸分子及其应用 |
| EP4463475A2 (en) * | 2022-01-14 | 2024-11-20 | Anjarium Biosciences AG | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
| WO2025110984A1 (en) * | 2023-11-21 | 2025-05-30 | Hydrogene Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2220222A4 (en) * | 2007-11-19 | 2011-10-12 | Univ California | NEW TEST FOR EGFR HEMMER |
| EP2424570A1 (en) * | 2009-04-30 | 2012-03-07 | Cytos Biotechnology AG | Influenza hemagglutinin compositions and uses thereof |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| PL2956477T5 (pl) * | 2013-02-15 | 2024-05-27 | Bioverativ Therapeutics Inc. | Zoptymalizowany gen czynnika viii |
| CA3178379A1 (en) * | 2013-09-12 | 2015-03-19 | Biomarin Pharmaceutical Inc. | Adeno-associated virus factor viii vectors |
| GB2526339A (en) * | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
| EP3331570A1 (en) * | 2015-08-03 | 2018-06-13 | Myodopa Limited | Systemic synthesis and regulation of l-dopa |
| MX2018003702A (es) | 2015-09-24 | 2018-04-30 | Biomarin Pharm Inc | Vectores del factor viii del virus adenoasociado, particulas viricas asociadas y formulaciones terapeuticas que las comprenden. |
| CN115141836B (zh) | 2015-10-28 | 2024-08-27 | 桑格摩生物治疗股份有限公司 | 肝特异性构建体、因子viii表达盒及其使用方法 |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| CN115287301A (zh) | 2016-03-03 | 2022-11-04 | 马萨诸塞大学 | 用于非病毒基因转移的末端封闭型线性双链体dna |
| KR102450833B1 (ko) * | 2016-04-15 | 2022-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 혈우병 a 치료용 유전자 요법 |
| BR112020001979A2 (pt) | 2017-08-01 | 2020-08-18 | Spark Therapeutics, Inc. | métodos de terapia genética do fator viii (fviii) |
| WO2019032898A1 (en) * | 2017-08-09 | 2019-02-14 | Bioverativ Therapeutics Inc. | NUCLEIC ACID MOLECULES AND USES THEREOF |
-
2020
- 2020-03-13 AU AU2020234713A patent/AU2020234713A1/en active Pending
- 2020-03-13 KR KR1020217029545A patent/KR20210151785A/ko active Pending
- 2020-03-13 WO PCT/US2020/022738 patent/WO2020186207A2/en not_active Ceased
- 2020-03-13 MA MA055313A patent/MA55313A/fr unknown
- 2020-03-13 BR BR112021017853A patent/BR112021017853A2/pt unknown
- 2020-03-13 MX MX2021011039A patent/MX2021011039A/es unknown
- 2020-03-13 JP JP2021554696A patent/JP2022524434A/ja active Pending
- 2020-03-13 CA CA3133255A patent/CA3133255A1/en active Pending
- 2020-03-13 US US17/437,123 patent/US12338275B2/en active Active
- 2020-03-13 CN CN202080036209.7A patent/CN113874513A/zh active Pending
- 2020-03-13 EP EP20769344.1A patent/EP3938523A4/en active Pending
- 2020-03-13 SG SG11202109850S patent/SG11202109850SA/en unknown
-
2021
- 2021-09-12 IL IL286284A patent/IL286284A/en unknown
-
2025
- 2025-02-03 JP JP2025016352A patent/JP2025073123A/ja active Pending
- 2025-05-21 US US19/214,171 patent/US20250282848A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025073123A5 (enExample) | ||
| Stillman et al. | Identification of the gene and mRNA for the adenovirus terminal protein precursor | |
| Munro | Iron regulation of ferritin gene expression | |
| JP2024073596A5 (enExample) | ||
| CN112040988A (zh) | 修饰的aav衣壳多肽用于治疗肌肉疾病 | |
| TW202128193A (zh) | 一種基於ｌｅａｐｅｒ技術治療ｍｐｓ ｉｈ的方法和組合物 | |
| JP2003527856A5 (enExample) | ||
| JP2019017390A (ja) | 特定遺伝子の発現を抑制するための方法および薬剤 | |
| CN112004559A (zh) | 用于在线粒体内表达蛋白质的核酸、包封有所述核酸的脂质膜结构体和它们的应用 | |
| BR112023015177A2 (pt) | Ácido nucleico compreendendo smn1 e mir-23a para tratamento da atrofia muscular espinhal, cassete de expressão, vetor de expressão, vírus recombinante, composição farmacêutica, uso e método relacionados | |
| Li et al. | RNA nanotechnology to build a dodecahedral genome of single-stranded RNA virus | |
| JP2003519241A (ja) | 二層型鉱物粒子に取り込まれた核酸を含む組成物 | |
| CN114438106B (zh) | Rv2779c基因及其表达产物作为抗结核分枝杆菌靶点的应用 | |
| TW202112797A (zh) | 經由靶向lama1基因治療肌肉萎縮症的方法 | |
| CA2211435A1 (fr) | Sequences amplificatrices derivees du gene de la desmine, vecteurs portant ces sequences et leurs utilisations pour la production de proteines | |
| JPWO2023039424A5 (enExample) | ||
| Bolwig et al. | Different binding site requirements for binding and activation for the bipartite enhancer factor EF-1A | |
| CN107073078B (zh) | 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物 | |
| CN111849981B (zh) | 基于PLIN1基因的sgRNA、质粒载体及其构建方法和应用 | |
| CN114533902A (zh) | 一种过表达lrrc15基因的质粒载体及其制备方法和应用 | |
| JPWO2022204093A5 (enExample) | ||
| JPWO2023025193A5 (enExample) | ||
| US20250121096A1 (en) | Engineered liver-specific enhancers and their applications | |
| RU2852567C2 (ru) | Сконструированный полипептид человеческого фактора VIII (hFVIII) с повышенной коагулирующей активностью, фрагмент выделенной нуклеиновой кислоты, вектор экспрессии (варианты), фармацевтическая композиция для лечения гемофилии A и способ ее лечения | |
| JPWO2023018858A5 (enExample) |